© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Elinzanetant Outcomes from the OASIS 1 and 2 Phase 3 Trials: A Read Out with Lead Investigator JoAnn Pinkerton, MD
May 29, 2024
The novel dual neurokinin-1,3 antagonist reduced VMS after just 1 week of treatment, Pinkerton said, and improved sleep and quality of life, as well. Hear more.
Plozasiran, an Investigational RNAi Therapy, Reduces Triglyceride Levels in Adults with Mixed Hyperlipidemia
May 28, 2024
Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.
Semaglutide Significantly Reduces Risk of Renal Events, MACE, Mortality in People with CKD, T2D in Final FLOW Trial Findings
May 24, 2024
The pluripotent GLP-1 mimetic reduced risk for renal disease endpoints by 24% and MACE by 18% plus significantly retarded decline in eGFR vs placebo, study authors reported.
US Drug Overdose Deaths Declined in 2023 for the First Time in 5 Years, CDC Reports
May 22, 2024
The 3% decline in 2023 compared with 2022 is "heartening news," CDC's Houry says, but the mission is far from accomplished.
Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes
May 22, 2024
Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.
Higher Prepregnancy BMI Category Linked to Increase in Poor Maternal and Neonatal Outcomes
May 21, 2024
Women with class 3 obesity before becoming pregnant have up to a 4.5-fold greater risk of composite maternal morbidity that includes preeclampsia, preterm delivery, DM.
Dupilumab in Replicate Phase 3 Trial Significantly Reduces COPD Exacerbations, Improves Lung Function, with PDUFA Date in Sight
May 21, 2024
Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.
Tezepelumab Cuts COPD Exacerbation Rate in High-Risk Population: COURSE Trial Highlights with Dave Singh, MD
May 20, 2024
Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.
Tezepelumab Reduces Rate of COPD Exacerbations in Individuals with Wide Range of Blood Eosinophil Levels: Phase 2a COURSE Trial Findings
May 20, 2024
ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.
ETHOS Post-Hoc Analysis: Dave Singh, MD, Highlights Breztri Reduction of Cardiopulmonary Risk in COPD
May 20, 2024
The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.